Idera Pharmaceuticals (IDRA) Given News Sentiment Rating of 0.14

Media coverage about Idera Pharmaceuticals (NASDAQ:IDRA) has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Idera Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.7876272495471 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news headlines that may have impacted Accern’s rankings:

Several equities analysts have weighed in on IDRA shares. Zacks Investment Research raised Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. BidaskClub lowered Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. ValuEngine lowered Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $4.00 target price on shares of Idera Pharmaceuticals in a research note on Tuesday. Three research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $4.48.

Idera Pharmaceuticals (NASDAQ IDRA) traded down 7.848% during midday trading on Tuesday, hitting $2.055. The stock had a trading volume of 2,723,544 shares. Idera Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $3.33. The stock’s market capitalization is $307.49 million. The company’s 50 day moving average price is $1.86 and its 200-day moving average price is $1.93.

Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Idera Pharmaceuticals had a negative net margin of 300.63% and a negative return on equity of 61.09%. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.20 million. Equities analysts anticipate that Idera Pharmaceuticals will post ($0.49) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Idera Pharmaceuticals (IDRA) Given News Sentiment Rating of 0.14” was published by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.

Insider Buying and Selling by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply